CAMP4 Therapeutics is a startup. Brouky records 1 investor associated with the company.
Develops antisense oligonucleotide (ASO) therapeutics that selectively upregulate gene expression by modulating regulatory RNA to address diseases caused by inadequate protein levels.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.